RT Journal Article
SR Electronic
T1 Levamisole and 5-fluorouracil therapy for resected colon cancer: a new indication
JF Canadian Medical Association Journal
JO CMAJ
FD Canadian Medical Association
SP 297
OP 301
VO 144
IS 3
A1 Skillings, J. R.
A1 Levine, M.
A1 Rayner, H. L.
A1 Eisenhauer, E.
A1 Erlichman, C.
A1 Germond, C.
A1 Kerr, I.
A1 Lofters, W.
A1 Maroun, J.
A1 Yoshida, S.
YR 1991
UL http://www.cmaj.ca/content/144/3/297.abstract
AB OBJECTIVE: To evaluate the benefits and risks of postoperative treatment with levamisole plus 5-fluorouracil (5-FU) in patients with colon cancer. DESIGN: Computerized searches of MEDLINE and CANCERLIT were performed, and the reference list of each retrieved article was checked. Only randomized trials of therapy with levamisole alone or combined with 5-FU for colon cancer without distant metastases were included. The studies were then evaluated with the use of four criteria. RESULTS: We reviewed six randomized trials, of which three satisfied our criteria. Two studies demonstrated a significant improvement in the survival rate with levamisole plus 5-FU among patients with colon cancer and pathologically confirmed metastases to adjacent lymph nodes (Dukes' stage C). A subgroup analysis in another study demonstrated a similar benefit. The toxic effects of the drugs were generally mild. The three other studies showed no difference in survival rates between the treatment groups; however, the samples were too small to detect a clinically or statistically important difference. CONCLUSIONS: Because many patients with colon cancer will suffer a relapse we recommend that they be offered the opportunity to participate in clinical trials of adjuvant therapy. For those with stage C disease not entering a clinical trial levamisole plus 5-FU is appropriate adjuvant therapy.